Dan Liu, Ph.D., AstraZeneca Postdoctoral FellowUniversity of California, San Francisco

My long-term goal is to understand the immune response and design efficient therapies against cancer and microbial infections.
Area of Research: Breast Cancer, Colorectal Cancer, Melanoma, All Cancers

LysoPS (lysophosphatidylserine) is a molecule that can inhibit T cell activation in the lab, and the enzyme (PS-PLA1) that produces lysoPS is upregulated in colorectal cancer. However, not much is known about this potential link between lysoPS and cancer, so Dr. Liu is exploring the signaling mechanisms and receptors that mediate lysoPS’s effects on T cells. To better define lysoPS’s molecular interactions and its effects on anti-cancer immune responses, Dr. Liu is investigating several target candidates—immune cell surface receptors—that appear to react with lysoPS. By characterizing the influence of lysoPS and the receptors it interacts with on T cell responses in the context of colorectal cancer, it could help guide approaches to mitigate any associated pro-cancer activity.

Projects and Grants

LysoPS and its receptors as regulators of T cell responses and tumorigenesis

University of California, San Francisco | All Cancers, Breast Cancer, Colorectal Cancer, Melanoma | 2017 | Jason G. Cyster, Ph.D.

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.